

# The Neuro4D Conference 2022

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE  
DISEASE  
DRUG  
DISCOVERY

**MONDAY  
MAY 16<sup>TH</sup>**

<b>7:30</b>		
Registration and Joint Breakfast (Please attach posters!)		
<b>9:00</b>		
Opening of the Conference by Andreas Köpke – bioExert		
<b>9:10</b>		
New Insights into Neurodegenerative Disease Induction and Progression	Characterization of biologically active tau species: What aggregates are disease relevant?	<b>Rakez Kayed</b> University of Texas Medical Branch, USA
<b>PANEL 09:40 – 10:40</b>		
AD Disease Mechanism	Structure of A $\beta$ -Fibrils from human AD brain and implication for function	<b>Marcus Fändrich</b> University of Ulm, Germany
	A $\beta$ dimers are antiprions that interfere with seeded nucleation <i>in vitro</i> and <i>in vivo</i>	<b>Carsten Korth</b> Neuropathology, Heinrich Heine University, Germany
Enabling Technology	Protein half-lives in human neuronal model systems used in CNS drug discovery	<b>Hannes Hahne</b> OmicScouts, Germany
<p>Panel Q&amp;A of Session Speakers Chair: Rakez Kayed, University of Texas Medical Branch, USA</p>		
<b>10:40 – 11:15</b>		
Coffee Break, Exhibition & Poster Session (All presenters are at their poster for discussion.)		
<b>PANEL 11:15 – 12:30</b>		
PD Disease Mechanism	Role of LRRK2 in maintaining nuclear envelope integrity and implications for Parkinson's disease	<b>Simone Engelender</b> Technion, Israel
Enabling Technology	Characterizing protein aggregates as tools to accelerate neurodegenerative diseases research	<b>Jacob McPhail</b> Stressmarq, Canada
PD Disease Mechanism	$\alpha$ -synuclein oligomers, but not inclusions, activate microglia in early Parkinson's disease	<b>Pierre Garcia</b> LCNP Neurodegeneration Group, Luxemburg
AD Disease Mechanism	Microglial cells In AD: good guys or bad guys?	<b>Knut Biber</b> Abbvie, Germany
<p>Panel Q&amp;A of Session Speakers Chair: Rakez Kayed, University of Texas Medical Branch, USA</p>		

# The Neuro4D Conference 2022

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE  
DISEASE  
DRUG  
DISCOVERY

**MONDAY  
MAY 16<sup>TH</sup>**

<b>12:30</b>		
Lunch		
<b>13:30</b>		
<b>From Disease Insights to Therapeutic Options</b>	A $\beta$ oligomers in Alzheimer disease: maximize target engagement, minimize target distraction	<b>Neil Cashman</b> University of British Columbia, Canada
<b>PANEL 14:00 – 15:00</b>		
<b>AD Drug Discovery</b>	Targeting soluble A $\beta$ protofibrils with lecanemab – from mutation to potential therapy for Alzheimer’s disease	<b>Lars Lannfelt</b> Bioarctic, Sweden
<b>PD Disease Mechanism</b>	Glycation as biomarker and drug target for intervention in synucleinopathies	<b>Tiago Outeiro</b> University of Göttingen, Germany
<b>PD Disease Model</b>	A new human $\alpha$ -synuclein A53T mouse model exhibiting multiple PD-like phenotypes	<b>Manuela Prokesch</b> QPS, Austria
<p><b>Panel Q&amp;A of Session Speakers</b> Chair: Neil Cashman, University of British Columbia, Vancouver, Canada</p>		
<b>15:00 – 17:00</b>		
<p><b>Coffee Break, Exhibition &amp; Poster Session</b> (All presenters are at their poster for discussion. Please vote for the best poster!) <b>One on One Meetings</b></p>		
<b>PANEL 17:00 – 18:00</b>		
<b>PD Drug Discovery</b>	ABBY-0805, a novel $\alpha$ -synuclein oligomer selective antibody as a potential therapy for Parkinson's disease	<b>Johanna Fälting</b> Bioarctic, Sweden
<b>PD Disease Model</b>	Update on animal models of $\alpha$ -synucleinopathy for use in therapeutic drug development	<b>James Koprich</b> Atuka Inc., Canada
<b>PD Drug Discovery</b>	Development of therapeutic substances for the disassembly of $\alpha$ -synuclein aggregates	<b>Antje Willuweit</b> Priavoid, Germany
<p><b>Panel Q&amp;A of Session Speakers</b> Chair: Neil Cashman, University of British Columbia, Canada</p>		
<b>18:00</b>		
Wine Tasting in the Foyer		
<b>19:00 – 22:00</b>		
Dinner (BBQ accompanied by fitting wines.)		
<b>END OF THE FIRST DAY</b>		

# The Neuro4D Conference 2022

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE  
DISEASE  
DRUG  
DISCOVERY

**TUESDAY  
MAY 17<sup>TH</sup>**

<b>7:30</b>		
Joint Breakfast and Poster Session (Please vote for the best poster!)		
<b>8:30</b>		
Scientific Introduction: Other proteopathic neurodegenerations	Polyglutamine aggregates seed Huntington's disease	<b>Erich Wanker</b> Max-Delbrück-Centre, Germany
<b>PANEL 9:00 – 10:00</b>		
Disease Mechanism	The importance of protein localization in Spinocerebellar Ataxia Type 3: From molecular insight to a treatment strategy	<b>Thorsten Schmidt</b> University Clinic Tübingen, Germany
	Molecular similarities and differences of TDP-43 aggregates in FTLD-TDP	<b>Manuela Neumann</b> University Clinic Tübingen, Germany
Drug Discovery	CNS-focused drug design – success stories	<b>Michael Thormann</b> Origenis, Germany
Panel Q&A of Session Speakers Chair: Erich Wanker, MDC, German		
<b>10:00 – 11:00</b>		
Coffee Break, Exhibition & Poster Session (All presenters are at their poster for discussion. Final chance to vote for the best poster!) Time for One on One Meetings		
<b>PANEL 11:00 – 12:00</b>		
Animal Models	Genetic variability in lab mice to improve translation of preclinical discoveries	<b>Manuel Buttini</b> Neuropathology and Animal Model Core Unit, Luxembourg
PD Biomarker	Parkinson's disease progression pathology: New insides for biomarker discovery?	<b>Walter Schulz-Schaeffer</b> Neuropathology Uni Saarland, Germany
AD Biomarker	Towards standardization of AD Biomarkers in CSF	<b>Timo Grimmer</b> Technical University Munich, Germany
Panel Q&A of Session Speakers Chair: Erich Wanker, MDC, German		
<b>12:00</b>		
Lunch		

# The Neuro4D Conference 2022

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE  
DISEASE  
DRUG  
DISCOVERY

**TUESDAY  
MAY 17<sup>TH</sup>**

13:00		
Clinical Studies in Neurodegenerative Diseases	Are disease modifying treatments finally here?	<b>Oliver Peters</b> Charité, Germany
PANEL 13:30 – 15:00		
AD Clinical Trial	Lessons learned: Developing gantenerumab as a disease modifying therapy	<b>Martin Traber</b> Roche, Switzerland
	PRI-002: towards clinical phase II – preclinical proof of concept and clinical phase I data	<b>Dieter Willbold</b> Priavoid, Germany
	Clinical, biomarker, and safety update from Lecanemab phase II proof of concept study and open label extension	<b>Chad Swanson</b> Eisai, USA – via MS TEAMS
	Milestones in Alzheimer's disease	<b>Samantha Budd Haeberlein</b> Biogen, USA – via MS TEAMS
<b>Pannel Q&amp;A of Session Speakers</b> <i>Chair: Oliver Peters</i>		
15:00		
Coffee Break (Please collect your posters!)		
15:30		
<b>Pannel Discussion</b> Success in the clinic? What is the expected outcome for future therapies? Can we all bear the costs? <b>Participants:</b> Oliver Peters, Neil Cashman, Martin Traber, Johanna Fälting <b>Moderator:</b> Andreas Köpke		
16:15		
<b>Poster Award</b> The best approach for the treatment of neurodegenerative diseases presented at Neuro4D 2022		
16:25 – 16:30		
Summary and Wrap-Up of the Conference		
16:30		
<b>END OF THE CONFERENCE AND DEPARTURE</b>		